3. Rb-switch and cell cycle regulation Ellisen and Haber Tumor-associated: - Rb - cyclinD - p16Ink4a - CDK4 Cell cycle activation
4. Rb-switch and cell cycle regulation Ellisen and Haber Tumor-associated: - Rb - cyclinD - p16Ink4a - CDK4 Cell cycle activation
5.
6.
7.
8.
9.
10.
11.
12.
13.
14. A selected list of oncolytic viruses in clinical trials the Scientist May 2007 ============== Jennerex (JX-594) Phase I/II Thymidine kinase deletion prevents replication in cells with low nucleotide pool. Vaccinia Neotropix (SVV-001) Phase I Naturally targets certain tumor cells Seneca Valley Virus Oncolytics (Reolysin) Phase I/II Naturally unable to infect cells with active PKR Reovirus Wellstat (PV701) ]; Hadassah Medical Organization (MTH-68H) Phase I Naturally unable to replicate in interferon-responsive cells Newcastle disease virus Mayo Clinic (MV-CEA) Phase I Engineered to target CD46 on tumor cells Measles virus BioVex (OncoVEXGM-CSF) Phase II ICP34.5 deletion restricts replication to cells with active replication Herpes simplex virus 1 Viralytics (A21) Phase I Targets DAF/intercellular adhesion molecule 1, which is overexpressed in cancer Coxsackie virus Onyx (O15) Phase III (canceled) Sunway Biotech of China (H101) Phase III E1B deletion restricts replication to cells with aberrant mRNA transport Adenovirus Companies/Institutions (candidate) Human trial status Selective targeting method Virus